Assorted News from the Last Week:
Precedent Setting: In a 14 to 6 vote, the FDA’s Oncologic Drug Advisory Committee (ODAC) agrees that eflornithine (DFMO) shows sufficient evidence to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma (HRBN) who are in remission and have completed multi-agent, multi-modality therapy.
The Food and Drug Administration (FDA) has approved Bosulif (bosutinib) for the treatment of children as young as 1 year old with newly diagnosed or resistant/intolerant to prior therapy chronic phase Philadelphia (Ph)-positive chronic myelogenous leukemia (CML).
Upcoming Webinars, Online Opportunities, and Meetings:
The Focused Ultrasound Foundation and National Brain Tumor Society are sponsoring a joint webinar on sonodynamic therapy (SDT) for brain tumors on October 11 at 11:00am ET. Learn more and register.
Register for the 55th SIOP in Ottawa, Canada on October 11-14. Experience 4 outstanding days of cutting-edge science, engaging debates, and networking with world-renowned experts. Learn more and register.
Free educational conferences offered by Triage Cancer on cancer-related topics including navigating finances, health and disability insurance, employment rights, advocacy, and more. Next one on October 14 from 10:00-6:30 CT. Learn more and register.
Join leaders and advocates across pediatric cancer as we come together on October 18-19 for CureSearch’s virtual 2023 Pediatric Early Development Symposium. Learn more and register.
On October 24 at 2:00 ET, Dr. Angela Mariotto, chief of the Data Analytics Branch in NCI’s Division of Cancer Control and Population Sciences, will showcase the combined potential of NCCR*Explorer and SEER*Stat, two tools available through the CCDI National Childhood Cancer Registry (NCCR). Through a live demonstration and real-world examples, attendees will learn how to harness these resources for cancer research and surveillance. Attendees will also have the chance to ask questions during the session’s Q&A. Register.
A Draft Scientific Integrity Policy of the National Institutes of Health was released for public comment. The draft policy articulates the procedures and processes in place at NIH that help maintain rigorous scientific integrity practices. Additionally, the draft policy proposes several new functions to further enhance scientific integrity at NIH and throughout the biomedical research enterprise. Comments will be accepted until November 9, 2023.
Phase 1/2 trial which aims to determine the safety and feasibility of anti-CD33 chimeric antigen receptor (CAR) expressing T cells (CD33CART) in children and adolescents/young adults (AYAs) with relapsed/refractory acute myeloid leukemia (AML). The trial will be done in two phases: Phase 1 will determine the maximum tolerated dose of CD33CART cells using a 3+3 trial design. Phase 2 is an expansion phase designed to evaluate the rate of response to CD33CART.
International Children’s Palliative Care Network (ICPCN) are excited to announce that the 2023 Digital Toolkit has been officially launched and is now available to download on the ICPCN #HatsOn4CPC website page. The #HatsOn4CPC annual campaign will be held on Friday 13th October 2023.
To help spread the word about the Childhood Cancer Data Initiative (CCDI), the National Cancer Institute has created a communications toolkit with a CCDI overview flyer, a one-pager with frequently asked questions about the CCDI Data Ecosystem, and sample social media posts and graphics. Access the toolkit, and feel free to reference, copy, and use its content for inspiration.
Sign up to receive a copy of CAC2's free childhood cancer news digest in your inbox each week.
- CAC2 Childhood Cancer Community News Digest (November 20-26)
- CAC2 Childhood Cancer Community News Digest (November 13-19)
- CAC2 Childhood Cancer Community News Digest (November 6-12)
- Fueling the Lifelong Fight Against Childhood Cancer: Nutrition for Patients and Survivors
- CAC2 Childhood Cancer Community News Digest (October 30- November 5)